company background image
TERN

Terns Pharmaceuticals NasdaqGS:TERN Stock Report

Last Price

US$9.53

Market Cap

US$471.9m

7D

20.5%

1Y

124.2%

Updated

04 Feb, 2023

Data

Company Financials +

Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Stock Report

Mkt Cap: US$471.9m

TERN Stock Overview

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

TERN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Terns Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Terns Pharmaceuticals
Historical stock prices
Current Share PriceUS$9.53
52 Week HighUS$10.67
52 Week LowUS$1.45
Beta0
1 Month Change12.38%
3 Month Change32.91%
1 Year Change124.24%
3 Year Changen/a
5 Year Changen/a
Change since IPO-48.18%

Recent News & Updates

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Recent updates

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

Shareholder Returns

TERNUS PharmaceuticalsUS Market
7D20.5%-0.5%1.7%
1Y124.2%4.6%-9.6%

Return vs Industry: TERN exceeded the US Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: TERN exceeded the US Market which returned -8.5% over the past year.

Price Volatility

Is TERN's price volatile compared to industry and market?
TERN volatility
TERN Average Weekly Movement16.9%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: TERN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: TERN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201641Senthil Sundaramhttps://www.ternspharma.com

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.

Terns Pharmaceuticals, Inc. Fundamentals Summary

How do Terns Pharmaceuticals's earnings and revenue compare to its market cap?
TERN fundamental statistics
Market CapUS$471.89m
Earnings (TTM)-US$58.77m
Revenue (TTM)US$1.00m

471.9x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TERN income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$0
Gross ProfitUS$1.00m
Other ExpensesUS$59.77m
Earnings-US$58.77m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.19
Gross Margin100.00%
Net Profit Margin-5,877.10%
Debt/Equity Ratio0%

How did TERN perform over the long term?

See historical performance and comparison